BIG
ACAD icon

Brooklyn Investment Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Brooklyn Investment Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,790
Closed -$81.8K – 674
2025
Q2 		$81.8K Buy
3,790
+3,394
+857% +$63.1K 0.01% 1054
2025
Q1 		$6.58K Buy
396
+208
+111% +$3.78K ﹤0.01% 1711
2024
Q4 		$3.45K Buy
+188
New +$3.03K ﹤0.01% 1325

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Brooklyn Investment Group's ACAD Position: Q3 2025 in Review

Brooklyn Investment Group sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 3,790 shares — an estimated $81.8K sold.

Brooklyn Investment Group first reported a position in ACAD in Q4 2024 and held it in 3 quarters. The position peaked at $81.8K in Q2 2025. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

  • Brooklyn Investment Group reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 3,790 Acadia Pharmaceuticals shares in Q3 2025, an estimated $81.8K.
  • Brooklyn Investment Group first reported a position in Acadia Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Brooklyn Investment Group's Acadia Pharmaceuticals position peaked at $81.8K in Q2 2025.
  • 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on Brooklyn Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.